Liu WeiZhen, Li Guanglai, Hölscher Christian, Li Lin
Rev Neurosci. 2015;26(4):371-83. doi: 10.1515/revneuro-2015-0005.
A growing body of evidence has linked two of the most common aged-related diseases: type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD). It has led to the notion that drugs developed for the treatment of T2DM may be beneficial in modifying the pathophysiology of AD. As a receptor agonist of glucagon-like peptide-1 (GLP-1R), which is a newer drug class to treat T2DM, geniposide shows clear effects in inhibiting pathological processes underlying AD, such as promoting neurite outgrowth. In the present article, we review the possible molecular mechanisms of geniposide to protect the brain from pathologic damages underlying AD: reducing amyloid plaques, inhibiting τ phosphorylation, preventing memory impairment and loss of synapses, reducing oxidative stress and the chronic inflammatory response, and promoting neurite outgrowth via the GLP-1R signaling pathway. In summary, the Chinese herb geniposide shows great promise as a novel treatment for AD.
越来越多的证据表明，两种最常见的老年相关疾病——2型糖尿病（T2DM）和阿尔茨海默病（AD）之间存在联系。这引发了一种观点，即开发用于治疗T2DM的药物可能有助于改变AD的病理生理过程。栀子苷作为一种治疗T2DM的新型药物类别——胰高血糖素样肽-1（GLP-1R）受体激动剂，在抑制AD潜在病理过程方面具有明显作用，如促进神经突生长。在本文中，我们综述了栀子苷保护大脑免受AD潜在病理损害的可能分子机制：减少淀粉样斑块、抑制τ蛋白磷酸化、防止记忆障碍和突触丧失、减轻氧化应激和慢性炎症反应，以及通过GLP-1R信号通路促进神经突生长。总之，中药栀子苷作为AD的一种新型治疗方法具有很大的潜力。
